Another well-controlled clinical study evaluated 279 subjects with mild to moderate plaque-type psoriasis (mean Body Surface Area at baseline was % with a range from 1% to 20%) of non-scalp regions. Subjects were treated twice daily for 2 weeks with OLUX (clobetasol propionate) Foam or Vehicle foam. The face and intertriginous areas were excluded from treatment. The efficacy of OLUX (clobetasol propionate) Foam in treating non-scalp psoriasis at the end of 2 weeks' treatment was superior to that of Vehicle foam. See Table 2 below.
Seventy-five patients with vitiligo were treated with intermittent topical applications of clobetasol propionate for varying times within a three-year period. The best results occurred in the facial lesions of Asian or black patients. Repigmentation of 90% to 100% was achieved in more than 80% of patients with vitiligo of the face and more than 40% of patients with vitiligo on other parts of the body. Progressive repigmentation continued even after the treatment stopped. Intermittent therapy helped to avoid the problems of adverse local effects from the use of potent adrenal steroids.